权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core 3: Bioinformatics and Biostatistics Core

核心3：生物信息学和生物统计学核心

基本信息

批准号：
10631168
负责人：
Yuan Liu
金额：
$ 25.49万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10631168
关键词：
Address Area Basic Science Bioinformatics Biological Biological Process Biometry Biostatistics Core Cells Clinical Clinical Research Clinical Trials Clinical Trials Design Collaborations Communication Critical Thinking Data Data Analyses Data Management Resources Development Dimensions Elements Ensure Experimental Designs Fostering Genes Goals Immunotherapy Information Systems Infrastructure Lung Lung Adenocarcinoma Malignant neoplasm of lung Manuscripts Medical Medical Informatics Methodology Molecular Molecular Immunology Monitor Mutate PTK2 gene Pathway interactions Patients Phase Preparation Program Research Project Grants Protocols documentation Reporting Reproducibility Research Research Activity Research Personnel Research Project Grants Resistance Resources Role STK11 gene Sampling Secure Statistical Data Interpretation Sting Injury Systems Biology Therapeutic Tumor Immunity Work anti-cancer cancer information system computational platform data acquisition data exchange data integration data integrity data management data sharing design experience innovation laboratory experiment lung cancer cell member molecular pathology multidisciplinary next generation novel programs prospective resistance mechanism shared database success translational study tumorigenesis

项目摘要

SUMMARY The Emory Lung Cancer P01 application aims to decipher the underlying mechanisms of immunotherapy resistance of LKB1-mut lung cancer and to seek possible therapeutic solutions with three interconnected projects to address this urgent unmet medical need. The function of the Bioinformatics and Biostatistics Core (Core 3) is to provide robust and transparent analytic strategies, sophisticated and integrated data analysis and management platforms, and state-of-the-art methodologies to maximize the success of the overall program through guiding and fostering data-driven interactions and collaborations. To support this goal, our Core 3 team of investigators has complementary expertise and extensive experience in biostatistics, bioinformatics, and medical informatics and data management that is critical for rigorous experimental design and streamlined data analysis, interpretation, sharing and management for basic mechanism-driven examination and clinical studies. Specifically, we will (i) provide comprehensive biostatistical expertise and resources in support to Lung Cancer P01 projects, including novel clinical trial design; (ii) provide a new integrative computational platform to support the elucidation of the molecular basis for GDH1 (Project 1), IAP/STING (Project 2), and FAK (Project 3)- dependent tumorigenesis in LKB1-deficient lung cancer with project leaders; and (iii) develop and maintain a centralized data acquisition and management system that is customized explicitly for this P01. Core 3 serves as a focal point of the P01 to ensure data integrity, scientific rigor, and sharing; and to foster collaborations between projects based on integrated analysis of mechanistic and clinical results and close interactions with each project and Core 1 and Core 2 through a shared database. Serving as a critical component of the P01 Program, Core 3 will be critical to further safeguard and elevate the entire research quality in this P01 to support the development of the next generation of effective anticancer immunity-based therapeutic strategies for patients with LKB1 mutated lung cancer.

总结